Nos publications COVID-19

Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic (Therapies 08/2020)
Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic (FCP 05/2020)
Genèse d’un site d’information sur le bon usage du médicament au cours de la pandémie (Actualités Pharmaceutiques 10/2020)

Drugs acting on renin angiotensin system and use in ill patients with COVID-19 (Therapies 08/2020)
Diabetes and COVID-19 (Therapies 08/2020)
Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review (Therapies 08/2020)
Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection (Therapies 08/2020)
Non-steroidal anti-inflammatory drugs and covid-19 (BMJ 04/2020)
Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence (Therapies 08/2020)
Renin-angiotensin-aldosterone system and COVID-19 infection (Ann Endocrinol 06/2020)
Potential drug–drug interactions associated with drugs currently proposed for COVID‐19 treatment in patients receiving other treatments (FCP 06/2020) (Version française)
Recommandations ANRS/SFPT pour le STP du Lopinavir/ritonavir et de l'hydroxychloroquine chez les patients traités pour une infection à SARS-CoV-2 (05/2020)
Modifications pharmacocinétiques liées à une infection aiguë. Exemples issus de la pandémie de SARS-CoV-2 (Therapies 10/2020)
Is the drug a scientific, social or political object? (Therapies 08/2020)

MetaEvidence COVID
Communiqué de l'Association Française des Centres d'Addictovigilance Méthadone et confinement lié au COVID-19 : assurer la continuité du traitement tout en maintenant la sécurité de son usage
Synthèses du réseau des centres régionaux de pharmacovigilance (MAJ 10/2020)